Future Direction of Intravenous and Subcutaneous Biologics

Dialing back doses of the two biologics saved $13.2 million over three years, researchers report at an American Society of Health-System Pharmacists meeting.

Researchers at Brigham and Women’s Hospital Harvard Medical School looked at clinical trials and compared these biologics to placebos to see how their treatments improve and manage severe asthma.

Their results argue for a change to parity between small-molecule agents and biologics when it comes to Inflation Reduction Act price negotiation timelines, the researchers say.

Clinicians have very strong concerns about the cost of biologics to treat food allergies, but despite these concerns, enthusiasm in the field for their use remains very high.

A recent study has found that biologics may have an effect on arterial wall inflammation and plaque composition, which offsets the influence of joint-derived inflammation in patients with arthritis.

Studies measuring patient preference stacked up in subcutaneous administration’s favor, according to a recently published review. The difference between subcutaneous and intravenous administration were less clear cut among the studies measuring health-related quality of life.